FDA Clearance Tracker · P220029
Optilume BPH Catheter System
Last checked: Nov 19, 2026Latest source record: Jun 30, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Jun 30, 2023
Approved
Time to decision
200 days
Received Dec 12, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P220029
- Device name
- Optilume BPH Catheter System
- Applicant
- Urotronic, Inc.
- Applicant location
- Minneapolis, MN
- Received
- Dec 12, 2022
- Decided
- Jun 30, 2023
- Decision
- Approved
- Supplements
- 4 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- GI, Urology & NephrologyUrology
FDA's approval statement
As written in FDA's record.
Approval for the Optilume BPH Catheter System indicated for the treatment of obstructive urinary symptoms associated with Benign Prostatic Hyperplasia (BPH) in men >= 50 years of age.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code QXB (Drug coated prostatic dilation catheter for benign prostatic hyperplasia).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Urotronic, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K250910 · Decided May 22, 2025 · 57 days after receipt
Device type: Dilator, Catheter, Ureteral (EZN) · GI, Urology & Nephrology
P210020 · Decided Dec 3, 2021 · 206 days after receipt
Device type: Catheter, Balloon, Urethral, Drug-Coated (QRH) · GI, Urology & Nephrology
K191061 · Decided Jan 2, 2020 · 255 days after receipt
Device type: Dilator, Urethral (KOE) · GI, Urology & Nephrology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.